Engineered T cells: the promise and challenges of cancer immunotherapy.
Engineered T cells: the promise and challenges of cancer immunotherapy.
复制标题
DOI:
10.1038/nrc.2016.97
复制
发表时间:
2016-08-23
期刊:
影响因子:
--
通讯作者:
Levine BL
中科院分区:
文献类型:
--
作者:
Fesnak AD;June CH;Levine BL
The immune system evolved to distinguish non-self from self to protect the organism. As cancer is derived from our own cells, immune responses to dysregulated cell growth present a unique challenge. This is compounded by mechanisms of immune evasion and immunosuppression that develop in the tumour microenvironment. The modern genetic toolbox enables the adoptive transfer of engineered T cells to create enhanced anticancer immune functions where natural cancer-specific immune responses have failed. Genetically engineered T cells, so-called 'living drugs', represent a new paradigm in anticancer therapy. Recent clinical trials using T cells engineered to express chimeric antigen receptors (CARs) or engineered T cell receptors (TCRs) have produced stunning results in patients with relapsed or refractory haematological malignancies. In this Review we describe some of the most recent and promising advances in engineered T cell therapy with a particular emphasis on what the next generation of T cell therapy is likely to entail.
登录
查看更多内容
DOI:
10.1098/rspb.1954.0054
发表时间:
1954-01-01
期刊:
PROCEEDINGS OF THE ROYAL SOCIETY SERIES B-BIOLOGICAL SCIENCES
影响因子:
--
作者:
BILLINGHAM, RE;BRENT, L;MEDAWAR, PB
通讯作者:
MEDAWAR, PB
影响因子:
45.3
作者:
Ahmed, Nabil;Brawley, Vita S.;Gottschalk, Stephen
通讯作者:
Gottschalk, Stephen
DOI:
10.1158/1078-0432.ccr-09-1322
发表时间:
2010-01-15
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
Ahmed N;Salsman VS;Kew Y;Shaffer D;Powell S;Zhang YJ;Grossman RG;Heslop HE;Gottschalk S
通讯作者:
Gottschalk S
影响因子:
11.2
作者:
Ahmed, Nabil;Ratnayake, Maheshika;Gottschalk, Stephen
通讯作者:
Gottschalk, Stephen
影响因子:
20.3
作者:
Bellucci, R;Alyea, EP;Ritz, J
通讯作者:
Ritz, J